Clinical assessment of the effect of tetrabenazine on functional scales in huntington disease: a pilot open label study.

Fekete R, Davidson A, Jankovic J.

Tremor Other Hyperkinet Mov (N Y). 2012;2. pii: tre-02-86-476-4. doi: 10.7916/D8DN43SC.

Quantitative proteomic analysis of human substantia nigra in Alzheimer's disease, Huntington's disease and Multiple sclerosis.

Chen S, Lu FF, Seeman P, Liu F.

Neurochem Res. 2012 Dec;37(12):2805-13. doi: 10.1007/s11064-012-0874-2.

Huntington's disease: new aspects on phenotype and genotype.

Shang H, Danek A, Landwehrmeyer B, Burgunder JM.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S107-9. doi: 10.1016/S1353-8020(11)70034-7.

[The life as a caregiver of a person affected by Chorea Huntington: multiple case study].

Winkler E, Ausserhofer D, Mantovan F.

Pflege Z. 2012 Oct;65(10):608-11. German.

Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.

Shirendeb UP, Calkins MJ, Manczak M, Anekonda V, Dufour B, McBride JL, Mao P, Reddy PH.

Hum Mol Genet. 2012 Jan 15;21(2):406-20. doi: 10.1093/hmg/ddr475.

[Schizophrenia-like psychotic symptoms in a patient with confirmed Huntington's disease: a case report].

Grabski B, Siwek M, Dudek D, Jaeschke R, Banaszkiewicz K.

Psychiatr Pol. 2012 Jul-Aug;46(4):665-75. Polish.

The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.

Reiner A, Lafferty DC, Wang HB, Del Mar N, Deng YP.

Neurobiol Dis. 2012 Jul;47(1):75-91. doi: 10.1016/j.nbd.2012.03.025.

WITHDRAWN: Potential role of ubiquitin ligase Ube3a in synaptic pathophysiology of Huntington's disease.

Maheshwari M, Jana NR.

Int J Dev Neurosci. 2012 Mar 31. pii: S0736-5748(12)00278-X. doi: 10.1016/j.ijdevneu.2012.03.239. [Epub ahead of print]

An evidence-based approach in the treatment of Huntington's disease.

Mestre TA, Ferreira JJ.

Parkinsonism Relat Disord. 2012 May;18(4):316-20. doi: 10.1016/j.parkreldis.2011.10.021. Review.

Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease.

Zacharoff L, Tkac I, Song Q, Tang C, Bolan PJ, Mangia S, Henry PG, Li T, Dubinsky JM.

J Cereb Blood Flow Metab. 2012 Mar;32(3):502-14. doi: 10.1038/jcbfm.2011.157.

Eugenics, Heredity, and Huntington's Disease: A Brief Historical Perspective.

Wexler A.

J Huntingtons Dis. 2012;1(2):139-41. doi: 10.3233/JHD-129007. No abstract available.

N-Acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington's disease.

Sandhir R, Sood A, Mehrotra A, Kamboj SS.

Neurodegener Dis. 2012;9(3):145-57. doi: 10.1159/000334273.

Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells.

Jeon I, Lee N, Li JY, Park IH, Park KS, Moon J, Shim SH, Choi C, Chang DJ, Kwon J, Oh SH, Shin DA, Kim HS, Do JT, Lee DR, Kim M, Kang KS, Daley GQ, Brundin P, Song J.

Stem Cells. 2012 Sep;30(9):2054-62. doi: 10.1002/stem.1135. Erratum in: Stem Cells. 2012 Nov;30(11):2602.

Downregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington's disease patients.

Chang KH, Chen YC, Wu YR, Lee WF, Chen CM.

PLoS One. 2012;7(9):e46492. doi: 10.1371/journal.pone.0046492.

A complementary diffusion tensor imaging (DTI)-histological study in a model of Huntington's disease.

Van Camp N, Blockx I, Camón L, de Vera N, Verhoye M, Veraart J, Van Hecke W, Martínez E, Soria G, Sijbers J, Planas AM, Van der Linden A.

Neurobiol Aging. 2012 May;33(5):945-59. doi: 10.1016/j.neurobiolaging.2010.07.001.